Trevi Therapeutics is leveraging the dual mechanism of its drug Haduvio to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF). The company plans to expand its treatment to other interstitial lung diseases (ILD) and refractory chronic cough. Positive Phase II trial results and ongoing pivotal studies support Trevi's shift to a specialty pharmaceutical platform focused on pulmonology. With competitors exiting the market, Trevi's strategy targets concentrated specialty networks, enabling efficient market entry and future growth without large commercial infrastructure, presenting a strong risk/reward profile for investors.
Mustafa Suleyman, co-founder of Microsoft’s DeepMind AI unit, criticized Anthropic’s method of training its AI chatbots, like Claude, to "push back" on commands and believe they might be conscious. Suleyman argues this approach is reckless and could ...
Gasoline prices jumped significantly, with WTI crude nearing $100 a barrel. Interactive Brokers senior economist Jose Torres suggests that oil prices above $120 a barrel pose a serious risk to consumer spending and could trigger a recession, especial...
Traders have invested $7 billion into the iShares 20+ Year Treasury Bond ETF (TLT) ahead of a Federal Reserve rate hike decision, hoping for a "jackpot mode" scenario where long-term yields drop significantly. This influx comes despite TLT's 35% loss...
Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-...
HIVE Digital Technologies, through its subsidiary BUZZ HPC, has formed a strategic partnership with ProCogia, an applied-AI and data engineering company. This collaboration will see ProCogia utilizing BUZZ HPC's Canadian data centers to provide AI so...
